Everest Organics Share Price

Everest Organics Limited, with its corporate operations in Hyderabad, functions as a pharmaceutical formulation manufacturing company in India. The company was incorporated in 1993 and is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediaries. Everest Organics Limited produces a comprehensive portfolio of APIs including Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Fenofibrate and Benzimidazole, with a total product lineup currently featuring over 30 APIs across various therapeutic categories manufactured at its state of the art USFDA approved facility. The company operates manufacturing units located in Sadasivpet in Telangana and Aroor in Andhra Pradesh and serves both domestic formulation companies and international clients across the globe.

Everest share price today on NSE and BSE signifies how market participants react to the company‘s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on production volumes, raw material costs including various chemical intermediates, capacity utilization rates, export demand, and the performance of its API and CRAMS segments. Everest stock price is influenced by various factors such as earnings, regulatory approvals from the USFDA, export registrations in target markets, changes in pharmaceutical manufacturing policies, and global API price trends. In the longer run, strategies such as expansion into new therapeutic categories, product portfolio diversification, development of contract research and manufacturing services, and value-added product development affect the stock market perceptions. All these factors need to be monitored closely to have an idea about the company‘s stock price movements.

Everest live share price provides real-time information about the last price traded, bid and ask prices, and trading volume. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Everest live price helps in observing short-term price volatility and shows how a stock moves relative to the broader BSE Healthcare index. Furthermore, monitoring Everest stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behavior. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company‘s valuation and overall investment outlook.

Everest Organics Limited Company Fundamentals

a. Company Background

Everest Organics Limited was incorporated in 1993 and is engaged in the manufacturing and sale of active pharmaceutical ingredients (APIs) and their intermediaries. The company operates primarily in the pharmaceutical segment, supplying products such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Fenofibrate, Tamsulosin Hcl, Benzimadizole, and various proton pump inhibitors including Pantoprazole and Esomeprazole Magnesium salts. The company operated its primary manufacturing facility at Sadasivpet in Telangana, and also had a facility at Aroor in Andhra Pradesh. It has also diversified into providing Contract Research and Manufacturing Services (CRAMS) to global pharma companies. The company exports its products to Europe, the United States, the Far East, the Middle East, and Latin/Central/South American countries. Over time, the company has expanded its production capacity and product portfolio to serve both domestic and international markets. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilization. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability, global demand for APIs, regulatory requirements in export markets, and input cost fluctuations.

b. Company Product Lines

• Active Pharmaceutical Ingredients (APIs): The company manufactures over 30 APIs across various therapeutic categories including Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Ciprofloxacin, Tamsulosin Hcl, Naproxen, Benzimidazole, and Dexlansoprazole at its USFDA approved facility

• Key Starting Materials and Intermediates: The company offers a portfolio of over 32 key starting materials and chemical intermediates customized to cater to the demands of clients globally for use in downstream API manufacturing

• Contract Research and Manufacturing Services (CRAMS): The company provides co-development and custom synthesis services for pharmaceutical companies looking to outsource API manufacturing for increased efficiency and affordable costs

• Generic Bulk Drugs: The company is involved in the manufacturing of bulk drugs as part of its API production operations, supplying formulation companies worldwide

• Specialty API Products: The company manufactures specialized API molecules for specific therapeutic applications across various medical fields

The product portfolio is structured to serve both domestic demand and select export markets across Europe, the United States, the Far East, the Middle East, and Latin America.

c. Company Revenue Model

• Domestic API sales generate revenue through sales of active pharmaceutical ingredients and their intermediaries to Indian pharmaceutical formulation companies and domestic institutional buyers

• Export sales contribute from international customers across Europe, the United States, the Far East, the Middle East, and Latin/Central/South American countries

• Contract Research and Manufacturing Services (CRAMS) provide revenue through co-development and custom synthesis services provided to global pharmaceutical companies

• Bulk drug manufacturing contributes revenue through the production and sale of pharmaceutical bulk drugs to downstream formulation companies worldwide

Revenue performance is primarily influenced by global demand for pharmaceutical ingredients, raw material costs, regulatory approvals for export markets, and selling price realizations in domestic and export markets.

d. Geographic Presence

• Manufacturing facility located in Sadasivpet, Medak District, Telangana, at the Hyderabad location

• Manufacturing facility also set up at Aroor, Andhra Pradesh for bulk drugs and formulations

• The registered and corporate office is located in Hyderabad, Telangana

• Domestic distribution network covers across India through direct supply channels to formulation companies

• Export markets include Europe, the United States, the Far East, the Middle East, and Latin/Central/South American countries, with the company exporting to over 40 countries globally

e. Key Milestones

• 1993: Incorporation of the company on February 19 and commencement of commercial operations

• 1995: Public issue in January to part-finance the project

• 1996: Commercial production of bulk drugs commenced at the Sadasivpet, Medak District facility in Hyderabad

• 2024: Initiated expansion of product portfolio with new API molecules

• 2025: Reported standalone net profit growth in certain quarters with significant year-on-year increase

• Recent years: Continued focus on product mix optimisation, operational efficiency improvements, and expansion of CRAMS services to global pharmaceutical clients

f. Industry Perspective

The API manufacturing industry is research-intensive and closely linked to demand from global formulation companies, generic drug manufacturers, and healthcare providers worldwide. Demand trends are influenced by chronic disease prevalence, patent expirations of blockbuster drugs, the growth of generic pharmaceutical markets, and increasing global healthcare access.

The industry is also affected by fluctuations in raw material prices such as chemical intermediates and solvents, along with energy and logistics costs. Regulatory compliance with quality standards from agencies like the USFDA, WHO-GMP, and European authorities increasingly shapes production practices and capital investment decisions.

Companies in the sector must manage patent expirations, intense global competition from Chinese and Indian API manufacturers, pricing pressure from buyers, and regulatory compliance while maintaining operational efficiency. These factors collectively influence financial performance and investor perception of firms like Everest Organics.

Everest Organics Limited Stock Market Presence: Listings & Index Representation

Everest Organics Limited is listed on the Bombay Stock Exchange (BSE) under the scrip code 524790 and trades under the security ID EVERESTO. Everest share price is actively traded on the BSE platform. The company is not currently listed on the National Stock Exchange (NSE). The company‘s market presence is within the small-cap segment of the market. Due to its size and sector focus, Everest stock price is generally tracked by investors interested in the API manufacturing and pharmaceutical industry.

Everest Organics Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap and BSE Healthcare indices. Everest share price finds representation in these indices based on its market standing. Everest stock price presence in these indices helps investors track the company relative to other API and pharmaceutical manufacturing companies.

Everest Organics Limited Stock Performance and Share Price History

Everest share price on the BSE reflects its position as an API and pharmaceutical ingredient manufacturer serving both domestic and international markets across multiple regions. Its performance is qualitatively driven by factors such as production capacity utilization at its Telangana facility, management of raw material costs including chemical intermediates, growth in export sales to regulated markets, and the ability to maintain strict regulatory compliance with USFDA standards. Investors compare the Everest share price movement with other API manufacturing companies to assess relative strength.

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings-driven price changes. Broader sector strength has also supported Everest share price. Beyond operational and sector influences, corporate actions such as the company‘s focus on expanding its CRAMS services and developing new API molecules can significantly affect share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short-term swings, even within a regulatory environment influenced by global pharmaceutical demand and regulatory compliance for export markets.

While short-term movements respond to events and announcements, longer-term valuation trends are better captured by the stock‘s annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger export demand and stable production margins, whereas a significant low aligns with market corrections or sector volatility. Everest share price extremes reflect the impact of global pharmaceutical pricing policies, regulatory approvals from agencies like the USFDA, and earnings visibility, providing a framework for understanding historical performance.

Everest stock price behaviour mirrors the trading patterns of a small-cap pharmaceutical company within India‘s API manufacturing ecosystem. The company’s diversified portfolio spanning proton pump inhibitors, fluoroquinolones, fibrates, and other therapeutic categories has shaped its price history. Over recent years, Everest share price has experienced periods of sharp gains followed by phases of consolidation. The company‘s shares have delivered substantial returns over the last year, reflecting strong investor interest in its export growth potential and product pipeline expansion.

The company’s performance has closely tracked global generic API demand and raw material cost cycles for chemical intermediates. Positive momentum appeared during periods of increased patent expirations that opened up generic API opportunities and favourable currency movements that boosted export realizations. However, periods of raw material cost inflation, intense competition from Chinese API manufacturers, and pricing pressure from buyers have led to consolidation in Everest share price. Profitability has shown variability, with certain quarters reporting significant profit growth while others have faced margin compression.

Despite disruptions, Everest shares have responded to strategic developments. The company maintains a USFDA approved manufacturing facility, a strong regulatory compliance focus, and a growing presence in key export markets across Europe, the United States, and the Far East.

Everest share price has declined for several recurring reasons. A drop in global generic API demand or pricing pressure from formulation buyers directly impacts profitability and leads to selling pressure. Changes in government policy regarding API import restrictions or manufacturing quality standards can also cause Everest share price to fall. Moreover, increases in operational costs without matching price increases compress margins, making the stock less attractive. Periods of global economic slowdown that affect pharmaceutical spending raise concerns about export order volumes, leading to price declines. The stock remains sensitive to raw material price movements and API pricing cycles. Broader market sell-offs in small-cap stocks also pull Everest share price down, regardless of the company‘s individual performance. Delays in regulatory approvals for new export markets or product registrations can also weigh on investor sentiment, resulting in lower valuation.

Everest Organics Limited Investor Relevance and Role in Portfolio

Everest Organics Limited is a holding in small-cap and pharmaceutical sector portfolios, offering exposure to API manufacturing, chemical intermediaries, and contract research services. Its inclusion in healthcare indices underscores its importance in India‘s pharmaceutical ingredient manufacturing space. The company’s USFDA approved manufacturing facility, its portfolio of over 30 API molecules across multiple therapeutic categories, its CRAMS services, and its export presence across Europe, the United States, the Far East, the Middle East, and Latin America make it a consideration for long-term allocations.

Everest share price receives influence from the company’s ownership structure. Everest equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India‘s pharmaceutical sector. Promoters hold a stable majority stake of approximately 59.61% of the company’s total shares, reflecting strong internal control as part of the founding promoter group. Domestic institutional investors hold a negligible stake of around 0.02% of the company‘s shares. Foreign institutional investors do not hold any stake in the company. Mutual funds do not own any stake in the company. The public holds the remaining stake, representing a significant retail shareholder base of approximately 40.37%. This investor base, with stable promoter participation and minimal institutional influence, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on API and generic bulk drug manufacturing.

Beyond fundamentals and ownership, the stock is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on raw material prices, export orders for APIs, and regulatory policy actions from bodies like the USFDA. The stock is available for trading on the BSE platform, allowing investors to take positions based on their outlook for the pharmaceutical ingredient sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements, such as changes in API import regulations or manufacturing quality standards.

Technical indicators provide additional insight into short-term momentum shifts in Everest stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader healthcare and small-cap sector trends. The stock‘s beta indicates a certain level of volatility compared to the broader market. The company’s debt levels reflect a manageable use of leverage consistent with its manufacturing operations. Return on equity and return on capital employed are at certain levels, and the company‘s book value per share serves as a reference point for valuation.

Overall, Everest Organics demonstrates a certain volatility profile compared to the broader market, with the stock generally considered to have moderate systematic risk. This makes it responsive to broader market movements and sector-specific factors such as raw material price fluctuations, regulatory approvals, and global API demand cycles.

Everest Organics Limited Sectoral Relevance and Peer Positioning

Everest Organics Limited sector relevance stems from its over three-decade presence in the API manufacturing industry since 1993, its position as a manufacturer of active pharmaceutical ingredients and their intermediaries across multiple therapeutic categories including proton pump inhibitors, fluoroquinolones, and fibrates, its portfolio of over 30 APIs manufactured at its USFDA approved facility, its portfolio of over 32 key starting materials and intermediates, its contract research and manufacturing services (CRAMS) providing co-development and custom synthesis to global pharmaceutical companies, its manufacturing facilities in Telangana and a former Andhra Pradesh plant, and its export presence across Europe, the United States, the Far East and the Middle East, and Latin/Central/South American countries, establishing it as a focused small-cap API provider supporting India‘s generic pharmaceutical and global healthcare ecosystem. Peer comparisons with companies like Aarti Drugs, Godavari Drugs, Sunil Healthcare, Mercury Laboratories, Vasundhara Rasayans, and Divis Laboratories focus on regulatory certifications, product mix, export intensity, and value-added API diversification rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API molecule pricing, global generic drug demand trends, and government pharmaceutical manufacturing policies further highlights Everest Organics positioning within India’s broader API manufacturing market.

Everest market cap highlights its position as a small-cap player within India‘s API and pharmaceutical sector. Based on recent data, the company‘s market capitalization fluctuates within a range depending on the reporting period. The market cap has moved in line with investor perceptions of the company’s growth potential following its focus on expanding its API product portfolio and CRAMS services. From earlier years through more recent periods, Everest market cap showed patterns as the company expanded its manufacturing capacity and product pipeline, followed by phases of consolidation. This pattern reflects investor confidence during favourable generic drug cycles with strong demand for affordable medicines, followed by contraction during challenging periods impacted by intense competition from Chinese API manufacturers and rising input costs. This decrease mirrors the correction in the share price from its annual high to recent levels.

Everest earnings trajectory demonstrates the impact of its operational execution in a competitive global API industry. In recent fiscal years, total income showed trends supported by the core API manufacturing business. Based on available data, the company’s revenue from operations has shown patterns from previous fiscal periods to more recent periods. Total income moved over the same period. Profit after tax has shown variability across quarters. However, quarterly performance has shown sequential improvement in certain periods, with profit after tax increasing from certain earlier quarters to later quarters, accompanied by growth in total income on a quarter-on-quarter basis. The company‘s domestic and export sales have shown patterns in recent fiscal periods. Everest share price earnings have faced headwinds from fluctuating raw material costs, competitive pressures from international API producers, and pricing pressure from buyers. However, the company has expanded its API product portfolio and CRAMS services to strengthen its market position. These developments illustrate the cyclical nature of the API manufacturing industry and the company’s position within this sector.

Everest EPS provides insight into its operational performance and income generation from API sales, chemical intermediates, and contract research services. The company reported certain levels of basic EPS in recent quarters that showed improvement compared to previous quarters and corresponding quarters of prior years, indicating positive movement. The trailing twelve-month EPS stands at certain levels depending on the reporting period. Everest EPS for recent full fiscal years showed patterns compared to prior fiscal years, reflecting the impact of demand cycles, regulatory approvals, and cost structures. The company has a face value per share and continues to be promoted by the founding promoter group. More recent quarterly performance suggests that Everest EPS has shown movement as the company benefits from operational optimization, improved product mix, and expansion into higher-value API segments.

Everest P/E ratio reflects how investors perceive the company‘s earnings relative to its revenue streams from API sales, chemical intermediates, and CRAMS services. Based on available data, the current P/E ratio stands at a significant premium compared to the industry average, indicating that the stock trades at a much higher multiple relative to its peers. The company’s profit after tax has shown patterns from previous fiscal years to the most recent fiscal year. Quarterly performance has demonstrated sequential movement, with profit after tax showing increases in some quarters, accompanied by movement in total income on a quarter-on-quarter basis. Everest P/E ratio reflects how market sentiment evolves alongside the company’s operational performance in a competitive global industry. The company‘s earnings before interest and taxes for recent quarters stood at certain levels reflecting operating efficiency. The net profit margin has shown movement in recent quarters compared to same quarters of prior years, indicating how the company manages cost structures and pricing power in a competitive API market.

Summary

Everest Organics Limited operates as a small-cap API and pharmaceutical ingredient manufacturer with a history dating back to 1993. Everest share price gets influenced by global demand for generic APIs, raw material costs, regulatory approvals from agencies like the USFDA, and the company’s export performance across Europe, the United States, and other regions. The company’s USFDA approved facility, portfolio of over 30 API molecules, and CRAMS services support its market position. Everest stock price reflects operational execution within the competitive API manufacturing sector. The ownership structure shows stable promoter holding of around 60% with minimal institutional participation and a significant retail majority.